ProfileGDS5678 / 1452942_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 86% 88% 85% 85% 84% 86% 85% 84% 88% 90% 89% 88% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0630783
GSM967853U87-EV human glioblastoma xenograft - Control 26.5318786
GSM967854U87-EV human glioblastoma xenograft - Control 36.8029888
GSM967855U87-EV human glioblastoma xenograft - Control 46.4902885
GSM967856U87-EV human glioblastoma xenograft - Control 56.4002485
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0584
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3137386
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3634285
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2607684
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8810288
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2338790
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1471389
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8361488
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5183386